25f272b8-11f5-4edc-9c54-f4115fc0a5de
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.500
- MYC_TARGETS_V1+0.400
- E2F_TARGETS+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.300
- ANGIOGENESIS+0.200
- DNA_REPAIR+0.200
- G2M_CHECKPOINT+0.200
- WNT_BETA_CATENIN_SIGNALING+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.100
- MTORC1_SIGNALING+0.100
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.400
- CHOLESTEROL_HOMEOSTASIS-0.400
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- APICAL_SURFACE-0.300
- APOPTOSIS-0.300
- BILE_ACID_METABOLISM-0.300
- COMPLEMENT-0.300
- FATTY_ACID_METABOLISM-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0edf46a2-3dfb-4bae-b642-281e05975bd1 | — | — | 0.919 |
| 2 | 59c50e1e-fc77-441e-93c2-f69c013f362c | — | — | 0.883 |
| 3 | SRR10899976 | — | — | 0.872 |
| 4 | SAMN03290896 | — | — | 0.861 |
| 5 | SAMN03290918 | — | — | 0.861 |
| 6 | BS_D144EJRQ | medulloblastoma | — | 0.857 |
| 7 | 9ca1da07-df79-4bbf-be81-0ef9de95ab0c | — | — | 0.857 |
| 8 | ERR2278885 | — | — | 0.853 |
| 9 | TCGA-LA-A7SW-01A-11R-A405-07 | — | cohortSQ1 | 0.852 |
| 10 | b2e80b2b-559c-424e-837d-fa1de6b912e7 | — | — | 0.847 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |